WebDec 2, 2024 · The median duration of adjuvant treatment was 27.4 months and 27.3 months for patients receiving AROMASIN or tamoxifen, respectively, within the IES study and 23.9 months for patients receiving AROMASIN or placebo within the 027 study. Median duration of observation after randomization for AROMASIN was 34.5 months and for tamoxifen … WebJul 23, 2015 · In the comparison of 2–3 years of tamoxifen then aromatase inhibitor to year 5 versus 5 years of tamoxifen, recurrence RRs favoured aromatase inhibitors significantly during years 2–4 (RR 0·56, 0·46–0·67) but not subsequently, and 10-year breast cancer mortality was lower with switching to aromatase inhibitors than with remaining on ...
Pfizer Announces Updated Trial Results for AROMASIN® …
WebApr 13, 2024 · About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636.1 (BQ) is one of the mechanisms that confer … WebJul 27, 2024 · Aromasin (chemical name: exemestane) is an aromatase inhibitor used to: to reduce the risk of hormone receptor-positive, early-stage breast cancer coming back (recurring) in post-menopausal women who have taken two to three years of tamoxifen; the women switch to Aromasin and complete 5 years of hormonal therapy after surgery doi 10.1136/bmj.h2361
Pfizer Announces Results from Trial of AROMASIN in …
WebOct 19, 2024 · Three aromatase inhibitors are currently approved in the United States for breast cancer treatment: anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara). These medications are used to treat breast cancer that's estrogen- or … WebFeb 1, 2024 · As noted previously, a switch strategy comparing outcomes among patients randomized to continued treatment with tamoxifen (for the recommended 5 years) versus those who switched to an AI... WebDec 2, 2024 · The median duration of adjuvant treatment was 27.4 months and 27.3 months for patients receiving AROMASIN or tamoxifen, respectively, within the IES study and 23.9 months for patients receiving AROMASIN or placebo within the 027 study. Median duration of observation after randomization for AROMASIN was 34.5 months and for tamoxifen … doi 10.1136/bmj.h217